Customer destocking and geopolitical uncertainty
Management cited destocking by customers due to geopolitical tensions, leading to slower revenue growth.
medium · management_commentaryAnthem Biosciences Limited — Q3 FY26
Anthem Biosciences reported Q3 FY26 consolidated revenue of 423 crore and EBITDA of 191 crore (41.8% margin), with PAT at 93 crore (20.3% margin).
bullish
medium
Financial stats pending filing verification
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Lumpy business nature and new product ramp-up delays
Analyst raised concern about lumpy revenue; management acknowledged that new product ramp-up may take time due to M&A and clinical trial risks.
medium · analyst_questionSemaglutide pricing pressure from China
Analyst questioned competitiveness; management expressed confidence in backward integration but noted Chinese pricing aggression.
medium · analyst_question